Compared with the control group, study participants who supplemented with taurine had a significant improvement in the primary outcome of reducing risk of metabolic syndrome, demonstrated by the following weighted mean changes: systolic blood pressure - 4 mm Hg diastolic blood pressure -1.5 mm Hg triglycerides -18.3 mg/dL fasting blood glucose -5.9 mg/dL There were also significant improvements in secondary outcomes as shown by the following weighted mean changes: LDL cholesterol - 6.5 mg/dL total cholesterol - 8.3 mg/dL fasting insulin -1.52 IU/L HOMA-IR (calculation of insulin resistance) - 0.7 There was no significant effect on HDL, body weight, and BMI
\n\n\n\n In gastrointestinal research specifically, the nitric oxide pathway is closely involved in maintaining mucosal integrity, which aligns directly with BPC-157s observed gastroprotective properties and its origin in gastric juice protein
In: Ramachandran A, Jaeschke H, editors
doi: 10.1124/jpet.107.120311 120 MedhurstA
Co-administration of L-carnitine in rats treated with lenvatinib for 2 weeks completely prevented the decrease in carnitine content and expression levels of carnitine-related and OXPHOS proteins, including carnitine/organic cation transporter 2, in the skeletal muscle